Effect of CS-514, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in hamsters

Biochim Biophys Acta. 1989 Sep 11;1005(1):65-71. doi: 10.1016/0005-2760(89)90032-5.

Abstract

Male golden hamsters fed a glucose diet as a model for cholesterol gallstone formation were used to investigate the effect of CS-514 on the lithogenicity of bile. Treatment with 0.05% (w/w) CS-514 in the diet for 1-4 weeks caused a decrease in plasma cholesterol and triacylglycerol levels. A marked increase in hepatic hydroxymethylglutaryl-CoA reductase activity in vitro and also an increased de novo cholesterol synthesis in the liver were induced by treatment with CS-514 for 1-4 weeks. The concentration of free cholesterol in liver microsomes and the cholesterol 7 alpha-hydroxylase activity were both decreased by treatment with CS-514 for 1 week, but were not affected by treatment for 4 weeks. The cholesterol output into bile and the lithogenic index of bile were double those of the control (glucose diet only) following treatment with CS-514 for 4 weeks, and the subsequent incidence of cholesterol gallstone formation was elevated. The content of free cholesterol and cholesterol ester in the liver was not affected by treatment with CS-514 for 4 weeks. These results suggest that long-term treatment with CS-514 causes a compensatory increase in the synthesis of hydroxymethylglutaryl-CoA reductase which leads to augmented hepatic de novo cholesterol synthesis and subsequent increased cholesterol output followed by an increase in the lithogenicity of bile. CS-514 apparently does not prevent cholesterol gallstone formation in those examples where the mechanism is thought to be due to augmented hepatic de novo cholesterol synthesis (type IV hyperlipidemia).

MeSH terms

  • Animals
  • Anticholesteremic Agents / pharmacology*
  • Bile / drug effects
  • Bile / metabolism
  • Bile Acids and Salts / metabolism
  • Cholelithiasis / chemically induced*
  • Cholesterol / blood
  • Cholesterol / metabolism*
  • Cricetinae
  • Dietary Carbohydrates
  • Glucose
  • Heptanoic Acids / pharmacology*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*
  • Lipid Metabolism*
  • Male
  • Mesocricetus
  • Microsomes, Liver / drug effects
  • Microsomes, Liver / metabolism*
  • Naphthalenes / pharmacology*
  • Pravastatin
  • Reference Values
  • Triglycerides / blood

Substances

  • Anticholesteremic Agents
  • Bile Acids and Salts
  • Dietary Carbohydrates
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Naphthalenes
  • Triglycerides
  • Cholesterol
  • Glucose
  • Pravastatin